Were Colgate-Palmolive (CL) share sale proceeds used to cover option costs?

Yes. The filing states that a portion of the share sale proceeds was delivered to Colgate-Palmolive to pay the $76.41 per-share option exercise price and related tax withholding, linking the open-market sales directly to funding the option exercises and associated taxes.

CL Form 4 reports multiple insider transactions

Q: What insider transaction did Colgate-Palmolive (CL) report for Panagiotis Tsourapas?

Colgate-Palmolive reported that COO Panagiotis Tsourapas exercised stock options and sold shares. He converted 50,000 options into common stock, then sold 35,000 shares on February 11, 2026 and 15,000 shares on February 12, 2026.

Q: How many Colgate-Palmolive (CL) shares did the COO sell and at what prices?

The COO sold 35,000 shares at a weighted average price of $94.6093 and 15,000 shares at a weighted average price of $97.8074. Both price figures reflect multiple trades within narrow price ranges disclosed in the footnotes.

Q: What stock options did the Colgate-Palmolive (CL) COO exercise in this Form 4?

He exercised stock options for 35,000 shares on February 11, 2026 and 15,000 shares on February 12, 2026 at an exercise price of $76.41 per share. These options were granted on September 10, 2020 and vested in one‑third increments.

Q: How many Colgate-Palmolive (CL) shares does the COO own after these transactions?

After the reported trades, the COO directly owns 10,415 Colgate-Palmolive common shares. He also has indirect ownership of 4,568 shares through the issuer’s 401(k) plan trustee and 60,745 shares held by a trust, plus 19,938 remaining stock options.

Tsourapas Panagiotis reported multiple insider transaction types in a Form 4 filing for CL.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Tsourapas Panagiotis reported multiple insider transaction types in a Form 4 filing for CL. The filing lists transactions totaling 150,000 shares at a weighted average price of $85.99 per share. Following the reported transactions, holdings were 19,938 shares.

Insider Trade Summary

Exercise and Sale: 50,000 shares ($958K approx. pre-tax spread)

Exercise and Sale 8 txns

Insider Tsourapas Panagiotis

Role COO, Eur., APac, Afr Eur, Skin

Sold 50,000 shs ($4.78M)

Approx. gross sale proceeds $4.78M

Approx. exercise cost $3.82M

Approx. pre-tax spread $958K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	15,000	$0.00	$0.00
Exercise	Common Stock	15,000	$76.41	$1.15M
Sale	Common Stock	15,000	$97.8074	$1.47M
Exercise	Stock Option (Right to Buy)	35,000	$0.00	$0.00
Exercise	Common Stock	35,000	$76.41	$2.67M
Sale	Common Stock	35,000	$94.6093	$3.31M
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 19,938 contracts (Direct); Common Stock — 10,415 shares (Direct); Common Stock — 4,568 shares (Indirect, By Issuer's 401(k) Plan Trustee); Common Stock — 60,745 shares (Indirect, By Trust)

Footnotes (5)

F1. Exercise of stock options awarded under the issuer's incentive compensation plan.
F2. Sale of shares with a portion of the proceeds delivered to the issuer for payment of the exercise price of options under the issuer's incentive compensation plan and the related tax withholding.
F3. Weighted average price, as these shares were sold in multiple transactions at prices ranging from $94.50 to $94.78 inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4. Weighted average price, as these shares were sold in multiple transactions at prices ranging from $97.74 to $97.89 inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5. Option became exercisable in one-third increments beginning on the first anniversary of the September 10, 2020 grant date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Colgate-Palmolive (CL) report for Panagiotis Tsourapas?

Colgate-Palmolive reported that COO Panagiotis Tsourapas exercised stock options and sold shares. He converted 50,000 options into common stock, then sold 35,000 shares on February 11, 2026 and 15,000 shares on February 12, 2026.

How many Colgate-Palmolive (CL) shares did the COO sell and at what prices?

The COO sold 35,000 shares at a weighted average price of $94.6093 and 15,000 shares at a weighted average price of $97.8074. Both price figures reflect multiple trades within narrow price ranges disclosed in the footnotes.

What stock options did the Colgate-Palmolive (CL) COO exercise in this Form 4?

He exercised stock options for 35,000 shares on February 11, 2026 and 15,000 shares on February 12, 2026 at an exercise price of $76.41 per share. These options were granted on September 10, 2020 and vested in one‑third increments.

How many Colgate-Palmolive (CL) shares does the COO own after these transactions?

After the reported trades, the COO directly owns 10,415 Colgate-Palmolive common shares. He also has indirect ownership of 4,568 shares through the issuer’s 401(k) plan trustee and 60,745 shares held by a trust, plus 19,938 remaining stock options.

What role does Panagiotis Tsourapas hold at Colgate-Palmolive (CL)?

Panagiotis Tsourapas is an officer of Colgate-Palmolive with the title COO, Eur., APac, Afr Eur, Skin. The Form 4 identifies him as a reporting person in this role, not as a director nor a ten percent owner of the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/13/2026 - 04:25 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tsourapas Panagiotis

(Last)

(First)

(Middle)

C/O COLGATE-PALMOLIVE COMPANY

300 PARK AVENUE

(Street)

NEW YORK

10022

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
COLGATE PALMOLIVE CO [ CL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	COO, Eur., APac, Afr Eur, Skin

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/11/2026		M⁽¹⁾		35,000	A	$76.41	45,415	D
Common Stock	02/11/2026		S⁽²⁾		35,000	D	$94.6093⁽³⁾	10,415	D
Common Stock	02/12/2026		M⁽¹⁾		15,000	A	$76.41	25,415	D
Common Stock	02/12/2026		S⁽²⁾		15,000	D	$97.8074⁽⁴⁾	10,415	D
Common Stock								4,568	I	By Issuer's 401(k) Plan Trustee
Common Stock								60,745	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$76.41	02/11/2026		M⁽¹⁾			35,000	⁽⁵⁾	09/10/2028	Common Stock	35,000	$0.0000	34,938	D
Stock Option (Right to Buy)	$76.41	02/12/2026		M⁽¹⁾			15,000	⁽⁵⁾	09/10/2028	Common Stock	15,000	$0.0000	19,938	D

Explanation of Responses:

1. Exercise of stock options awarded under the issuer's incentive compensation plan.

2. Sale of shares with a portion of the proceeds delivered to the issuer for payment of the exercise price of options under the issuer's incentive compensation plan and the related tax withholding.

3. Weighted average price, as these shares were sold in multiple transactions at prices ranging from $94.50 to $94.78 inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. Weighted average price, as these shares were sold in multiple transactions at prices ranging from $97.74 to $97.89 inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. Option became exercisable in one-third increments beginning on the first anniversary of the September 10, 2020 grant date.

	/s/ Kristine Hutchinson, Attorney-in-Fact	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR